Impact of Methicillin Resistance on Outcomes of Staphylococcus aureus Bacteremia at a U.S. Center, 2023–2024
Open Forum Infectious Diseases · 02.06.2026 · 13 (6)
DOI: 10.1093/ofid/ofag354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 06.06.2026. Verfasst von Joseph B Ladines-Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Penn Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, T32 training grant.
Abstract (Originalsprache)
Background
Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has historically been associated with worse outcomes than methicillin-susceptible S. aureus (MSSA), but MRSA epidemiology has evolved and contemporary data are mixed. We evaluated whether methicillin resistance is independently associated with S. aureus bacteremia (SAB) outcomes.
Methods
We conducted a retrospective cohort study of adults with a first-episode SAB at two academic hospitals from January 17, 2023 to January 16, 2024. The primary outcome of in-hospital mortality/hospice discharge was compared between MRSA and MSSA. Secondary outcomes included intensive care unit (ICU) admission, 7-day readmission, metastatic complications, infective endocarditis, and recurrent bacteremia. Multivariable logistic regression was used to estimate adjusted odds ratios (aORs), with propensity score matching as sensitivity analysis.
Results
Among 329 patients with SAB, 140 (42.6%) had MRSA and 189 (57.4%) had MSSA. Compared with MSSA, MRSA was associated with younger age, lower body mass index, higher injection drug use prevalence, more skin and soft tissue sources, and lower illness severity. After covariate adjustment, methicillin resistance was not associated with mortality/hospice discharge (aOR 1.03, 95% CI 0.49–2.12), ICU admission (aOR 1.09, 95% CI 0.61–1.94), 7-day readmission (aOR 1.51, 95% CI 0.51–4.67), metastatic complications (aOR 0.98, 95% CI 0.47–2.05), infective endocarditis (aOR 1.02, 95% CI 0.42–2.45), or recurrent bacteremia (aOR 2.43, 95% CI 0.92–6.76). Findings were consistent in propensity-matched analyses.
Conclusions
In this contemporary academic cohort, methicillin resistance was associated with distinct patient characteristics but not worse short-term outcomes. Host factors, illness severity, and infection source may be more important prognostic determinants.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Penn Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- The College of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Joseph B Ladines-Lim, Aidan Nemiroff, Michael Z David
Förderung
- NIGMS NIH HHS
- T32 training grant
Zitieren
APA
Ladines-Lim, J. B., Nemiroff, A., Cressman, L., & David, M. Z. (2026). Impact of Methicillin Resistance on Outcomes of Staphylococcus aureus Bacteremia at a U.S. Center, 2023–2024. Open Forum Infectious Diseases, 13(6). https://doi.org/10.1093/ofid/ofag354
Vancouver
Ladines-Lim JB, Nemiroff A, Cressman L, David MZ. Impact of Methicillin Resistance on Outcomes of Staphylococcus aureus Bacteremia at a U.S. Center, 2023–2024. Open Forum Infectious Diseases. 2026;13(6). doi:10.1093/ofid/ofag354
BibTeX
@article{LadinesLim2026,
author = {Ladines-Lim, Joseph B and Nemiroff, Aidan and Cressman, Leigh and David, Michael Z},
title = {Impact of Methicillin Resistance on Outcomes of Staphylococcus aureus Bacteremia at a U.S. Center, 2023–2024},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {6},
doi = {10.1093/ofid/ofag354}
}
EUVIMED